Pattern of adverse drug reactions reported by the community pharmacists in Nepal
The pharmacovigilance program in Nepal is less than a decade old, and is hospital centered. This study highlights the findings of a community based pharmacovigilance program involving the community pharmacists.
Objectives: To collect the demographic details of the patients experiencing adverse drug reactions (ADR) reported by the community pharmacists; to identify the common drugs causing the ADRs, the common types of ADRs; and to carry out the causality, severity and preventability assessments of the reported ADRs.
Methods: The baseline Knowledge-Attitude-Practices (KAP) of 116 community pharmacists from Pokhara valley towards drug safety was evaluated using a validated (Cronbach alpha=0.61) KAP questionnaire having 20 questions [(knowledge 11, attitude 5 and practice 4) maximum possible score 40]. Thirty community pharmacists with high scores were selected for three training sessions, each session lasting for one to two hours, covering the basic knowledge required for the community pharmacists for ADR reporting. Pharmacist from the regional pharmacovigilance center visited the trained community pharmacists every alternate day and collected the filled ADR reporting forms.
Results: Altogether 71 ADRs, from 71 patients (37 males) were reported. Antibiotics/ antibacterials caused 42% (n=37) of the total ADRs followed by non steroidal anti-inflammatory drugs [25% (n=22)]. Ibuprofen/paracetamol combination accounted for ten ADRs. The most common type of ADR was itching [17.2 % (n=20), followed by generalized edema [8.6 % (n=10)]. In order to manage the ADRs, the patients needed medical treatment in 69% (n=49) of the cases. Over two third (69%) of the ADRs had a ‘possible’ association with the suspected drugs and a high percentage (70.4%) were of ‘mild (level 2)’ type. Nearly two third [64.7 % (n=46)] of the ADRs were ‘definitely preventable’.
Conclusion: The common class of drugs known to cause ADRs was antibacterial/ antibiotics. Ibuprofen/ Paracetamol combination use of the drug was responsible for more number of ADRs and the most common ADRs were related to dermatological system. Strengthening this program might improve safe use of medicines in the community.
2. Sharma, HB, Gautam, RP, Vaidya, S. Eds. District development profile of Nepal. Kathmandu, Informal Sector Research and Study Center, 2001.
3. Kafle KK, Gartoulla RP, Pradhan YM, Shrestha AD, Karkee SB, Quick J D. Drug retailer training: experiences from Nepal. Soc Sci Med. 1992;35(8):1015-1025.
4. Kafle KK, Madden JM, Shrestha AD, Karkee SB, Das PL, Pradhan YM, Quick JD. Can licensed drug sellers contribute to safe motherhood? A survey of the treatment of pregnancy related anemia in Nepal. Soc Sci Med. 1996;42(11):1577-1588.
5. Blum NL. Rational pharmaceutical management project United States Pharmacopoeia: Drug information Development. A case study, Nepal Available at www.usp.org/pdf/EN/dqi/nepalCaseStudy.pdf (Accessed on 12th December 2009)
6. Das BP, Deo SK, Jha N, Rauniar GP, Naga Rani MA. Knowledge, attitudes and practices (KAP) regarding the management of diarrhea by pharmacists and licensed drug sellers in eastern Nepal. Southeast Asian J Trop Med Public Health. 2005;36(6):1562-1567.
7. Drug Bulletin of Nepal. 2004/2005; 15 (2) Available at http://www.dinon.org/publications/dbn-vol16.pdf (Accessed on May 21st 2008)
8. Palaian S, Izham MI, Mishra P. Developing a community based Pharmacovigilance program in Western Nepal: a significant initiative to ensure drug safety. J Clin Diagnos Res. 2008;2:905-906.
9. Palaian S, Mohamed Izham MI, Mishra P, Alam K, Poudel A, Khanal S. ADR reporting by community pharmacists in Nepal. J Pharm Pract Res. 2008;38:331-332.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
11. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229-2232.
12. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.
13. Stein CM, Gora NP, Macheka BM. Self-medication in urban and rural Zimbabwean communities. Br J Clin Pharmacol. 1989;27:741-747.
14.Wachter DA, Joshi MP, Rimal B. Antibiotic dispensing by drug retailers in Kathmandu, Nepal. Trop Med Int Health. 1999;4:782-788.
15. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-1205.
16. Palaian S, Mishra P, Shankar PR. Systemic adverse drug reactions: a preliminary report from the regional pharmacovigilance center, western Nepal. Pak J Pharm Sci. 2008;21(4):465-467.
17. Jha N, Bajracharya O, Namgyal T. Prevalence of adverse drug reactions with commonly prescribed drugs in different hospitals of Kathmandu valley. Kathmandu Univ Med J (KUMJ) 2007;5(4):504-510.
18. Shrestha R, Shakya S, Bista D. Case studies of hospitalized patients due to drug related complications. Kathmandu Univ J Sci Eng Technol 2006; 2 http://www.ku.edu.np/kuset/second_issue/o2/Rajeev.pdf (Accessed on 3rd January, 2010)
19. Palaian S, Izham MIM, Mishra P. Evaluation of the knowledge, attitude and practices on adverse drug reactions and pharmacovigilance among healthcare professionals in a Nepalese hospital- a preliminary study. Int J Pharmacol. 2008;6(1).
20. Lee A, Thomas SHL. Adverse drug reactions. In: Walker R and Edward C. Clinical pharmacy and Therapeutics, 2003, 3rd edition Churchill Livingstone, 33-46.
21. Ibañez-Cuevas V, Lopez-Briz, E, Guardiola-Chorro, MT. NSAID induced Gastropathy Prevention Programme Group. Pharmacist intrvention reduces gastropathy risk in patients using NSAIDs. Pharm World Sci. 2008;30:947-954.
22. Shankar PR, Partha, P, Shenoy N, Brahmadathan KN. Investigation of antimicrobial use pattern in the intensive treatment unit of a teaching hospital in western Nepal. Am J Infect Control. 2003;31:410-414.
23. Paudel KR, Sharma M, Das BP. Prevalence of antimicrobial chemotherapy in hospitalized patients in the department of internal medicine in a tertiary care center. Nepal Med Coll J. 2008;10:91-95.
24. Khanal B, Sharma SK, Bhattacharya SK, Bhattarai NR, Deb M, Kanungo R. Antimicrobial susceptibility patterns of Salmonella enterica serotype typhi in eastern Nepal. J Health Popul Nutr. 2007;25:82-87.
25. Sarkar C, Das B, Baral P. Analgesic use in dentistry in a tertiary hospital in western Nepal. Pharmacoepidemiol Drug Saf. 2004; 13: 729-733.
26. Palaian S, Shankar PR, Hegde C, Hegde M, Ojha P, Mishra P. Drug utilization pattern in dental outpatients in tertiary care teaching hospital in western Nepal. N Y State Dent J. 2008;74:63-67.
27. Poudel A, Palaian S, Shankar P.R, Jayasekera J, Izham MIM. Irrational fixed dose combinations in Nepal: need for intervention. Kath Univ Med J (KUMJ). 2008;6:399-405.
28. Mishra P, Subish P, Gupta S, Shankar PR, Bista D, Chhetri AK, Bhandari RB. Pattern and economic impact of cutaneous adverse drug reactions; initial experiences from the regional pharmacovigilance center, Western Nepal. Int J Risk Saf Med. 2006;18:163-171.
29. Ghosh S, Acharya LD, Rao PGM. Study and evaluation of the various cutaneous adverse drug reactions in Kasturba hospital, Manipal. Ind J Pharm Sci. 2006;68:212-215.
The authors hereby transfer, assign, or otherwise convey to Pharmacy Practice: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print pr epublish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to Pharmacy Practice with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.